Document is current

Article History

Received: 15 August 2024

Accepted: 5 November 2024

First Online: 19 November 2024

Declarations

:

: The study was conducted in accordance with the Declaration of Helsinki and in compliance with current Good Clinical Practice guidelines. The protocols were approved by the local institutional review board (METC AMC, reference number METC 2019_032).

: A written informed consent was obtained from all participants.

: Written informed consent was obtained from the patient for publication of this study and accompanying images.

: NN reports funding from the Dutch Heart Foundation (Dekker 03–007-2023–0068) and the European Atherosclerosis Society and is co-founder of Lipid Tools.JK was supported by the Dutch Heart Foundation (Senior Scientist Dekker grant (03–004-2021-T045) and was funded by the European Union (ERC, ENDOMET-STEER, 101076407). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.FR and DL declare they are inventors on a patent filed ("Fucoidan as a ligand for P-selectin imaging”. WO/2010/116209 (PCT/IB2009/052791)) related to the work presented in this manuscript. No other potential conflicts of interest relevant to this article exists.MS was supported by the fellowships of Sigrid Jusélius Foundation and Orion Research Foundation, Helsinki, Finland, and the European Atherosclerosis Society.All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.